Provided by Tiger Trade Technology Pte. Ltd.

California Resources

64.20
+0.25000.39%
Post-market: 65.481.28+1.99%18:57 EDT
Volume:1.82M
Turnover:117.22M
Market Cap:5.69B
PE:15.47
High:64.84
Open:64.43
Low:63.67
Close:63.95
52wk High:66.35
52wk Low:30.97
Shares:88.60M
Float Shares:88.50M
Volume Ratio:1.32
T/O Rate:2.06%
Dividend:1.57
Dividend Rate:2.44%
EPS(TTM):4.15
EPS(LYR):4.15
ROE:10.07%
ROA:6.42%
PB:1.55
PE(LYR):15.47

Loading ...

California Resources Corp - Increases Commitment Amount From $1.15 Bln to $1.45 Bln - SEC Filing

THOMSON REUTERS
·
Nov 01, 2025

California Resources Corporation Raises Credit Facility to $1.45 Billion with New Lenders

Reuters
·
Nov 01, 2025

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

GlobeNewswire
·
Oct 31, 2025

Natera’s PROCEED-CRC Study: A Step Forward in Early Cancer Detection

TIPRANKS
·
Oct 28, 2025

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

GlobeNewswire
·
Oct 27, 2025

Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

GlobeNewswire
·
Oct 27, 2025

Cautious Hold Rating on Merus: Promising Efficacy in CRC Amidst Limited Data

TIPRANKS
·
Oct 25, 2025

Nyse Order Imbalance 87023.0 Shares on Sell Side

THOMSON REUTERS
·
Oct 21, 2025

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results

Benzinga_recent_news
·
Oct 20, 2025

What's Going On With Summit Therapeutics Stock On Monday?

Benzinga_recent_news
·
Oct 20, 2025

Alphamab Oncology’s JSKN003 Receives Breakthrough Therapy Designation for HER2+ CRC

TIPRANKS
·
Oct 20, 2025

Sector Update: Energy Stocks Increase Friday Afternoon

MT Newswires Live
·
Oct 18, 2025

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

GlobeNewswire
·
Oct 17, 2025

California Resources Corporation Breaks Ground on California’s First Carbon Capture and Storage Project in Kern County

Reuters
·
Oct 17, 2025

Leerink Partners Keeps Their Buy Rating on California Resources Corp (CRC)

TIPRANKS
·
Oct 16, 2025

The Ultimate Biotech Stock to Buy With $50 Right Now

Motley Fool
·
Oct 14, 2025

Critica Limited Strengthens Jupiter Project with R&D Funding and CRC Partnership

TIPRANKS
·
Oct 14, 2025

U.S. RESEARCH ROUNDUP-American Express, BlackRock, Domino's Pizza

Reuters
·
Oct 13, 2025

California Resources Corp : Jefferies Cuts Target Price to $68 From $71

THOMSON REUTERS
·
Oct 13, 2025

California Resources Is Maintained at Overweight by JP Morgan

Dow Jones
·
Oct 10, 2025